1. Scrip
  2. >>Business

Will ViiV’s Regulatory Stance Delay Access To Cabotegravir Despite MPP Deal?

Paxlovid Precedent A Concern

 
• By Vibha Ravi

Scrip looks at the contours of MPP’s recent sub-licensing deal for ViiV Healthcare’s cabotegravir with Cipla, Aurobindo and Mylan, along with pricing dynamics and precedents to evaluate a few barriers to access

AIDS logo with red ribbon
AIDS Caused One Death Every Minute In 2021 And Prevention Is Essential • Source: Shutterstock

The Medicines Patent Pool (MPP) recently sublicensed ViiV Healthcare’s cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) to Aurobindo Pharma Limited, Cipla Limited and Viatris Inc.’ Mylan Pharmaceuticals Inc., a move that will allow generic versions of the antiretroviral drug to be manufactured.

AIDS led to one death every minute in 2021, data from the joint United Nations Programme on HIV/AIDS (UNAIDS) show. “If current trends continue, we expect that, in 2025, we’ll have 1.2 million people newly infected with HIV in that year

More from Business

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.